OpenAI正加快在医疗健康领域的布局，CEO山姆·阿尔特曼亲自参与医院销售洽谈[1]。今年1月，包括西达赛奈医疗中心、HCA Healthcare在内的8家大型医疗系统成为OpenAI企业级医疗工具的客户[1]。过去半年内，公司推出三款医疗领域新产品，包括面向临床医生的ChatGPT版本和ChatGPT Health工具[1]。
目前，OpenAI称每周有数百万临床医生使用ChatGPT，全球每周超2.3亿名用户通过ChatGPT获取医疗建议[1]。为提升医疗应用的准确性，OpenAI组建了260多名医生的团队优化健康类问答内容[1]。位于佛罗里达州的AdventHealth表示，使用OpenAI模型处理行政事务后相关工作耗时减少80%[1]。
不过，OpenAI的医疗应用仍存在风险。2024年2月的《自然-医学》研究发现，ChatGPT Health在超过半数有必要就医的病例中没有建议患者就医[1]。此外，OpenAI已收到美国几个州的传票，调查内容涉及健康数据处理与安全问题[1]。
OpenAI is making a major strategic push into healthcare, with CEO Sam Altman personally involved in hospital sales negotiations [1]. The company has launched three new medical products over the past six months, including a ChatGPT version tailored for clinical physicians and ChatGPT Health, a consumer-facing health tool [1]. By January 2025, OpenAI had already established partnerships with eight major healthcare systems, including Cedars-Sinai Medical Center and HCA Healthcare [1].
The company's healthcare ambitions reflect the significant market opportunity, with the medical and health sector representing approximately 18 percent of the overall U.S. economy [1]. Currently, more than 230 million users worldwide access medical advice through ChatGPT each week [1]. OpenAI reports that hundreds of thousands of clinical physicians use ChatGPT on a weekly basis [1]. At AdventHealth, headquartered in Florida, the use of OpenAI's model for administrative tasks has reduced the time required for such work by 80 percent [1].
To address accuracy concerns in medical contexts, OpenAI has assembled a team of over 260 doctors to optimize health-related question-and-answer content [1]. This effort comes as the company faces regulatory scrutiny; OpenAI has received subpoenas from several U.S. states investigating its handling and security of health data [1]. A February 2024 study published in Nature Medicine found that ChatGPT Health failed to recommend seeking medical care in more than half of cases where such care was necessary [1].
